Moscow - A Russian institute developing one of the country's potential coronavirus vaccines hopes to start its final stage testing in a small section of the general public in mid-August, the RIA news agency cited the institute's director as saying on Monday.
Early results from the first small-scale human trial of the vaccine developed by the Gamaleya Institute in Moscow has shown it to be safe for use, according to a separate RIA report on Sunday. This will be equivalent to a Phase III trial, since people getting the vaccine will remain under supervision, RIA reported, citing Ginsburg.
Human trials of the Gamaleya Institute's vaccine began on June 18, with nine volunteers receiving one dose, and another nine testing the prospective booster dose.
Law Law Latest News, Law Law Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Russia may start phase III trial of Covid-19 vaccine in mid-AugustA Russian institute developing one of the country’s potential coronavirus vaccines hopes to start its final stage testing in a small section of the general public in mid-August, the RIA news agency cited the institute’s director as saying on Monday. Globally, of 19 experimental COVID-19 vaccines in human trials, only two are in final Phase III trials — one by China’s Sinopharm and another by AstraZeneca and the University of Oxford.
Source: SowetanLIVE - 🏆 13. / 63 Read more »
Source: eNCA - 🏆 49. / 51 Read more »
SA's first Covid-19 vaccine trial brings hopeThe AU-commissioned programme intends to have injection by first quarter of next year.
Source: IOL - 🏆 46. / 51 Read more »